Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis, Dupilumab Study

Trial Profile

Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis, Dupilumab Study

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Apr 2018

At a glance

  • Drugs Dupilumab (Primary)
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Apr 2018 Planned initiation date changed from 1 Mar 2018 to 1 May 2018.
    • 22 Feb 2018 Planned initiation date changed from 19 Feb 2018 to 1 Mar 2018.
    • 09 Feb 2018 Planned initiation date changed from 12 Feb 2018 to 19 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top